Following confirmation of efficacy and safety through an open‐labeled, randomized, controlled phase 3 trial, VN was approved for gene augmentation therapy in RPE65‐associated retinal dystrophy in 2017 (Russell et al. 2017). Here, RPE65 is linked to inherited retinal dystrophy.